Publications by authors named "Everton Mandley"

Claim this Profile
L
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, Yue Chen, Shubao Zhou, Everton Mandley

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous Deletion.
Zenon Konteatis, Jeremy Travins, Stefan Gross, Katya Marjon, Amelia Barnett, Everton Mandley

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Peter Kalev, Marc L Hyer, Stefan Gross, Zenon Konteatis, Chi-Chao Chen, Everton Mandley

Cancer Cell· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Katya Marjon, Michael J Cameron, Phong Quang, Michelle F Clasquin, Everton Mandley

Cell Rep· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis